

May 7, 2014



OPKO Creates Global Supply Chain Structure

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), announced that it is expanding its global presence with the establishment of a global supply chain operation in Ireland. OPKO is recruiting employees immediately for a range of initial positions, including material and vendor selection, quality assurance, quality control, manufacturing, logistics and sales functions to support the ongoing global launch of its 4Kscore™ diagnostic test and in anticipation of the commercial launch of RAYALDEE™. OPKO's supply chain operation in Ireland is also expected to manage the global supply of other products over the next several years. The Irish operation will also serve as a global holding company for many of OPKO's non-U.S. subsidiaries and as a platform for future strategic acquisitions.

"Ireland's government and universities have a proven record of commitment and robust partnerships with regard to education and training for pharmaceutical manufacturing, quality assurance, quality control and supply logistics. As we build our global supply chain and quality team, we are excited to choose Ireland for its highly skilled and educated workforce," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

About OPKO Health, Inc.

We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations around our global supply chain operations in Ireland, expectations around the launch and commercialization of our products, including the 4Kscore and RAYALDEE, whether the 4Kscore, RAYALDEE or any of our products in development will be successfully commercialized, whether the Irish operations will manage the global supply of our products and serve as a platform for future strategic acquisitions, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future

results, that RAYALDEE, the 4Kscore, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

OPKO Health, Inc.

Steven D. Rubin or Adam Logal, 305-575-4100

Source: OPKO Health, Inc.